We report the synthesis of new compounds 4− 35 based on structural modifications of different moieties of previously described lead UCM-2550. The new nonpiperazine derivatives, representing second-generation agonists, were assessed for binding affinity, selectivity, and functional activity at the 5-HT 1A receptor (5-HT 1A R). Computational β 2 -based homology models of the ligand−receptor complexes were used to explain the observed structure−affinity relationships. Selected candidates were also evaluated for their potential in vitro and in vivo neuroprotective properties. Interestingly, compound 26 (2-{6-[(3,4-dihydro-2H-chromen-2-ylmethyl)amino]hexyl}-tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione) has been characterized as a high-affinity and potent 5-HT 1A R agonist (K i = 5.9 nM, EC 50 = 21.8 nM) and exhibits neuroprotective effect in neurotoxicity assays in primary cell cultures from rat hippocampus and in the MCAO model of focal cerebral ischemia in rats.
■ INTRODUCTION
G protein-coupled receptors (GPCRs) are the largest family of membrane-bound receptors and transmit chemical signals into a wide array of different cell types. These proteins account for more than the 50% of the druggable genome and present a wide range of opportunities as therapeutic targets in areas including cancer, cardiac dysfunction, diabetes, central nervous system disorders, obesity, inflammation, and pain. 1 Indeed, drugs targeting members of this integral membrane protein superfamily represent the core of modern medicine because they account for the majority of best-selling drugs and about 40% of all prescription pharmaceuticals on the market. Nevertheless, there is still much to be learned about how GPCRs work and how they can be selectively modulated. Technologies designed specifically to tackle the GPCR challenge, such as cell-based screening assays and structural studies, are blossoming and reinforcing their potential for future drug discovery. 2−4 Consequently, GPCRs are among the most heavily investigated drug targets, and there is broad consensus that they will remain at the hub of drug development activities for the foreseeable future.
Serotonin (5-hydroxytryptamine, 5-HT) receptors constitute an important GPCR family composed of 14 members which have been classified into seven families (5-HT 1−7 ) based on amino acid sequences, pharmacology, and intracellular mechanisms. 5, 6 The 5-HT 1A receptor (5-HT 1A R) subtype has been the most extensively studied, its agonists and partial agonists being clinically used in the treatment of anxiety and depression. 7−9 The 5-HT 1A R is also responsible for the lack of unwanted side-effects in some atypical antipsychotic drugs. 10, 11 Besides these well-established therapeutic areas, other interesting nonpsychiatric perspectives have emerged for 5-HT 1A R agents in recent years, mostly related to neuroprotection, cognitive impairment, Parkinson's disease, or pain treatment. 12−15 In particular, it is known that the selective 5-HT 1A R agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 1) and other 5-HT 1A R agonists attenuate excitotoxicity (Chart 1), 16 showing neuroprotective properties in models of global and focal cerebral ischemia in mice, rats, and gerbils. 17, 18 Indeed, the selective 5-HT 1A R agonists repinotan [(R)-(−)-2-{4-[(chroman-2-ylmethyl)amino]butyl}-1,1-dioxobenzo[d]-isothiazolone (BAYx3702, (−)-2)] and piclozotan (SUN N4057) have demonstrated neuroprotective properties in phase IIb clinical trials for treatment of ischemic stroke, although the former has been discontinued. 19−21 Stroke is the third leading cause of death in adults and the main neurologic cause of disability in the elderly. It is recognized that cell death in the ischemic penumbra may be prevented by different classes of compounds acting at different steps along the ischemic cascade. Yet, pharmacological treatment with available so-called neuroprotective drugs has not been successful to improve clinical outcome in patients. Today, several studies strongly support the potential interest of 5-HT 1A R activation in the search for neuroprotective strategies. 22−24 Because stroke is such an important cause of mortality worldwide, even small clinical benefits may have a huge positive impact on public health. In this context, our goal is the development of a 5-HT 1A R agonist as an anti-ischemic agent.
During the last years, our group has been involved in a wide research program aimed at developing new arylpiperazines with high affinity for the 5-HT 1A R. 25−31 Some of these ligands have been pharmacologically characterized as potent 5-HT 1A R agonists endowed with anxiolytic properties. 32, 33 In the present work, the previously reported high-affinity ligand 3 (UCM-2550) 31 was used as starting point to design and synthesize new compounds 4−35 devoid of piperazine ring (Tables 1−4) . In these series, we have systematically modified different structural moieties of lead compound 3: the amide subunit, spacer 1, spacer 2, and the aromatic system (Chart 2). The new synthesized nonpiperazine ligands 4−35, representing secondgeneration 5-HT 1A R agonists, were assessed for binding affinity, selectivity, and functional activity at the receptor. The mode of binding proposed in our computational model of ligand− receptor complex explained the observed structure−affinity relationships. Selected candidates have also been evaluated for their potential in vitro and in vivo neuroprotective properties. In particular, compound 26 [X = (CH 2 ) 3 , Y = N, n = 0, Z = (CH 2 ) 6 , m = 1, Ar = chroman-2-yl] was characterized as a potent 5-HT 1A R agonist and exhibited neuroprotective effect in neurotoxicity assays in primary cell cultures from rat hippocampus and in a model of focal cerebral ischemia in rats. (Tables 1−4) were obtained following the synthetic route described in Scheme 1.
■ RESULTS AND DISCUSSION

Synthesis. Target compounds 4−35
In general, 1,3-thiazolidine-2,4-dione, hydantoins 34−36 36−39 [n = 0; Y = N; X = (CH 2 ) 3 , (CH 2 ) 4 , CH 2 SCH 2 , and S(CH 2 ) 2 , respectively] or diketopiperazines 37 40,41 [n = 1; Y = N; X = (CH 2 ) 3 , and (CH 2 ) 4 , respectively] were alkylated with the appropriate commercially available α,ω-dibromo or -dichloro derivative in the presence of sodium hydride and N,Ndimethylformamide (DMF) to yield the corresponding halogenated intermediates 42−60. Subsequent treatment of 42−60 with commercial or previously described amines 38−40 61−64 provided final compounds 4−35. Enantiopure amines (+)-and (−)-64 were prepared following a new procedure based on the kinetic resolution of racemic ethyl chromane-2-carboxylate [(±) -65] 41 with Pseudomonas fluorescens lipase, radioligand (see Experimental Section for details). All compounds were assayed as hydrochloride salts. The competitive inhibition assays were first performed at a fixed dose of 10 −6 M, and the complete dose−response curve, at six different concentrations of the ligand, was determined for those compounds that presented a displacement of the radioligand over 55%. The inhibition constant K i was calculated from the IC 50 value using the Cheng−Prusoff equation, 43 and the values in Tables 1−4 are the mean of two to four independent experiments. Compounds exhibiting high affinity for the 5-HT 1A R (K i < 50 nM) were tested for selectivity over other serotonin receptors as well as α 1 -adrenergic and dopamine D 2 receptors (Tables 2−4 (Table 1) . Notably, analogue 9− containing a single methylene unit as spacer 2 and chromane as Ar− is the most potent compound. No significant differences were observed between racemic compound (±)-9 (K i = 1.23 nM) and the most active isomer (−)-9 (K i = 1.9 nM). Thus, the (±)-chroman-2-ylmethyl group appeared as the most promising for the Ar and spacer 2 moieties. Using this terminal group, the influence of the amide subunit was studied in compounds 18−23 (Table 3) . Modifications in the amide subunit do not have a significant influence because all compounds in the series exhibit high to very high 5-HT 1A R binding affinity [K i (18−23) = 2.4−34 nM]. Considering both a f f i n i t y d a t a a n d s y n t h e t i c a v a i l a b i l i t y , 1 , 3 -dioxoperhydropyrrolo[1,2-c]imidazole and 1,3-thiazolidine-2,4-dione were selected as the amide subunits in compounds 24− 35 for further optimization of spacer 1. In this series, the best results were obtained for compounds with saturated aliphatic spacers containing 3−6 methylene units (K i = 1.23−12.9 nM) ( Table 4 ). The influence of the cis (29)/trans (28) configuration of the four-methylene spacer was also assessed, the trans isomer being more potent [K i (28) 44 partial agonists dobutamine (2Y01) or salbutamol (2Y04), or agonists carmoterol (2Y02) or isoprenaline (2Y03), 45 the β 2 -adrenergic receptor bound to the partial inverse agonist carazolol (2RH1), 46 the agonist BI-167107 (3P0G), 47 or the irreversible agonist FAUC50 (3PDS), 48 the dopamine D 3 receptor in complex with the antagonist eticlopride (3PBL), 49 Figure 1A ). The fact that the Asp 3.32 and Asn 7.39 combination of side chains is also present in the 5-HT 1A R ( Figure 1A ) led us to propose a similar hydrogen bond network as in adrenergic receptors. The model depicted in Figure 1B shows the secondary protonated amine (NH 2 + ) and the oxygen atom of the chromane system of 26 anchored between Asp 3.32 and Asn 7.39 , the Ar moiety expanded toward transmembrane helix (TM) 5, and the amide subunit extended toward TM 2. Thus, compound 26 occupies the orthosteric binding pocket that is located between the extracellular segments of TMs 3 and 5−7, and the recently named minor binding pocket located between the extracellular segments of TMs 2, 3, and 7. 51 The binding of 26 to the 5-HT 1A R resembles the binding of FAUC50 covalently bound to the His 2.64 Cys mutant β 2 -adrenergic receptor through a disulfide bond. 48 This mode of binding of 26 explains the observed structure− affinity relationships. (i) The length of spacer 1 can be extended to eight methylene units without a large decrease in binding affinity. Increase of the number of methylene units Figure 1B ). Compounds 10−17 without this aromatic ring (single-ring Ar systems) cannot achieve these interactions, leading to inactive compounds ( Table 1 ). The importance of these interactions is also revealed in the structure−affinity relationships of compounds 4−7. Figure 1C shows a detailed view of the bicyclic Ar systems of ligands 26 (white/gray), 4 (orange), 5 (olive), 6 (purple), and 7 (blue) in the orthosteric binding cavity of the 5-HT 1A R for comparison purposes. Clearly, all active compounds (5, 6, 7) position the aromatic ring in a similar manner to compound 26, facilitating the interaction with Trp 6.48 and Phe 6.52 . In contrast, the 1-naphthyl system of compound 4 is placed toward the extracellular side that impedes the key interactions with Trp 6.48 and Phe (Table 5 ). In general, a correlation between in vitro and in vivo potency was observed.
Neuroprotective Effect. In Vitro Assays. The in vitro neuroprotective effect was evaluated in primary neuronal cultures from rat hippocampus. Neurotoxicity assays consisted of determining the protection against cell death induced by serum deprivation, glutamate toxicity, or oxygen-glucose deprivation. The 5-HT 1A R agonist 1 and the neuroprotective agent 2 were also included in these studies for comparative purposes. The results show that some of the new 5-HT 1A R agonists afforded neuroprotection, similar to that of reference compounds, against cell death in primary hippocampal cultures exposed to serum and oxygen-glucose deprivation (Table 6 ). In particular, ligand (±)-9, endowed with high affinity (K i = 1.23 nM, Table 1 ), selectivity (Table 2) , and agonist potency (EC 50 = 16.3 nM, Table 5 ) for the 5-HT 1A R, was approximately equipotent to agonist 1 against apoptotic cell death induced by serum deprivation and against excitotoxic cell death (Table 6 ). However, all other new 5-HT 1A R agonists tested were virtually devoid of neuroprotective effect on neuronal cell death induced by glutamate. Notably, compounds 25 and 26 afforded a high neuroprotection against cell death in cultures exposed to oxygen−glucose deprivation, similar to that of reference compound (−)-2 ( Table 6 ). It should be noted that, in general, the protective effect was not strictly concentrationdependent, so only the highest effect found is shown in the table. Such a lack of a concentration-or dose-dependent effect has been reported for other 5-HT 1A R agonists in previous studies. 53, 54 In Vivo Models. Compound 26, behaving as an effective neuroprotective agent in vitro, was subsequently tested in an in vivo model of neuroprotection. The selected animal model was the focal ischemia in rats induced by the permanent occlusion of the middle cerebral artery (MCAO), which represents an adequate model for ischemic stroke in humans. One day later, brain sections were stained with the mitochondrial dye 2,3,5-triphenyltetrazolium chloride (TTC), and cortical and subcortical infarct volumes were calculated by image analysis. Tested compounds were administered by continuous iv infusion. In these in vivo experiments, the 5-HT 1A R agonist (−)-2, previously reported as neuroprotective agent, was also assayed for comparative purposes. The results are shown in Table 7 . Administration of a low dose (40 μg/kg/h) of compound 26 for 4 h immediately after MCAO significantly reduced the total infarct volume measured 24 h later (∼29% reduction), compared to the corresponding saline-treated controls. The protective effect was more marked in cortical areas (∼35% protection) than in subcortical nuclei, where the protection did not reach statistical significance. Virtually identical results were obtained with the same dose (40 μg/kg/h) of reference agent (−)-2 infused over 4 h ( Table 7) . The results herein reported suggest the interest of further pharmacological development of compound 26 and related drugs.
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■ CONCLUSIONS
Herein we report the synthesis of new compounds 4−35, based on systematic modifications of different structural moieties present in the previously reported lead arylpiperazine 3: the amide subunit, spacer 1, spacer 2, and the aromatic system (Chart 2). The new nonpiperazine derivatives were assessed for binding affinity at the 5-HT 1A R and selectivity over other serotonin receptors (Tables 1−4 ). Computational β 2 -based homology models revealed that ligands occupy the orthosteric pocket of the receptor between TMs 3, 5−7, and a minor binding pocket between TMs 2 and 7, explaining the observed structure−affinity relationships. Determination of the functional activity at the h5-HT 1A R receptor revealed that identified high-affinity ligands (K i < 25 nM) represent second-generation 5-HT 1A R agonists (Table 5 ). New characterized 5-HT 1A R agonists were also evaluated for their potential in vitro and in vivo neuroprotective properties. Compounds (±)-9, 25, and 26 afforded protection against cell death in neurotoxicity assays in primary neuronal cultures from rat hippocampus (Table 6 ). Interestingly, in the rat model of focal ischemia, iv infusion of compound 26 after MCAO significantly reduced the cerebral infarct volume (∼29%), the protection being more marked in cortical areas (∼35%). The protective effect of 26 was virtually identical to that of compound (−)-2, a 5-HT 1A R agonist that has been previously described as a neuroprotective agent (Table 7) 13 C, 50 MHz) at the UCM's NMR facilities. Chemical shifts (δ) are expressed in parts per million relative to internal tetramethylsilane; coupling constants (J) are in hertz (Hz). The following abbreviations are used to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), qt (quintet), m (multiplet), br (broad). 2D NMR experiments (HMQC and HMBC) of representative compounds were carried out to assign protons and carbons of the new structures. Elemental analyses (C, H, N or C, H, N, S) were obtained on a LECO CHNS-932 apparatus at the UCM's analysis services and were within 0.5% of the theoretical values, confirming a purity of at least 95% for all tested compounds. Optical rotations were recorded on a Perkin-Elmer 241 polarimeter using a 1 dm path length; concentrations are given as g/100 mL. Analytical thinlayer chromatography (TLC) was run on Merck silica gel plates (Kieselgel 60 F-254) with detection by UV light (254 nm), ninhydrin solution, or 10% phosphomolybdic acid solution in ethanol. Flash chromatography was performed on glass column using silica gel type 60 (Merck, particle size 230−400 mesh, for final compounds) or on a Varian 971-FP flash purification system using silica gel cartridges (Varian, particle size 50 μm, for intermediates). Unless stated otherwise, starting materials, reagents, and solvents were purchased as high-grade commercial products from Sigma-Aldrich, Acros, Lancaster, Scharlab, or Panreac and were used without further purification. Anhydrous tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl and used immediately.
The following compounds were synthesized according to described 25 2-(1-naphthyl)ethylamine (61), 38 2-(2-naphthyl)ethylamine (62), 38 quinolin-2-ylmethylamine (63), 39 3,4-dihydro-2H-chromen-2-ylmethylamine (64), 57 and ethyl chromane-2-carboxylate ((±)-65). 41 Collected data for compounds 4−35 refer to free bases, and then hydrochloride salts were prepared prior to mp determination, elemental analyses, and biological assays. Spectroscopic data of all described compounds were consistent with the proposed structures. 
(2CO).
General Procedure for the Synthesis of Haloalkyl Derivatives 42−60. To a suspension of 1 equiv of 1,3-thiazolidine-2,4-dione, hydantoins 36−39 or diketopiperazines 40,41 in anhydrous DMF (1.2 mL/mmol), 1 equiv of NaH (60% in mineral oil) was added at room temperature and under an argon atmosphere. The reaction mixture was stirred at 60°C for 1 h, and a solution of 2 equiv of the corresponding α,ω-dibromo or -dichloro derivative in anhydrous DMF (0.5 mL/mmol) was added dropwise. The reaction was heated at 110°C for 3 h. Then, the solvent was removed under 3-(5-Bromopentyl)-1,3-thiazolidine-2,4-dione (58) . Obtained from 1,3-thiazolidine-2,4-dione and 1,5-dibromopentane in 61% yield. Chromatography: hexane/EtOAc, 9:1.
3-(6-Bromohexyl)-1,3-thiazolidine-2,4-dione (59) H, and 13 C NMR spectra were consistent with those described for racemic (±)-65. The enantiomeric excess (ee) was determined by chiral HPLC analysis carried out on an Agilent 1200 series system (Chiralpak IC, hexane/i-PrOH 95:5, 1.2 mL/min, 38 bar, 280 nm); (S)-enantiomer t r = 7.93 min (minor); (R)-enantiomer t r = 11.71 min (major): 97% ee. The aqueous layer was acidified with concentrated HCl to pH 1.0 and extracted with EtOAc (3 × 750 mL). The organic layers were dried (Na 2 SO 4 ) and evaporated to afford the free carboxylic acid, which was esterified by treatment with EtOH and H 2 SO 4 at reflux for 2 h. The solvent was evaporated, and the residue was suspended in dichloromethane and washed with a saturated aqueous solution of NaHCO 3 and brine. The organic layer was dried (Na 2 SO 4 ) and evaporated to afford ester 65, which was resubjected to enzymatic hydrolysis with lipase P30 for optical purity enhancement. Following the hydrolysis procedure previously described, (2S)-(+)-chromanecarboxylic acid was obtained. Then, this acid was esterified as described previously in this experiment to afford enantiopure ester (+)-65 as an oil in 38% global yield: 
Synthesis of (2R)-(−)-and (2S)-(+)-3,4-dihydro-2H-chromen-2-ylmethylamine ((−)-and (+)-64)).
To a mixture of enantiopure ester (−)-or (+)-65 (4.7 g, 22.6 mmol) and ammonium chloride (280 mg, 5.5 mmol), aqueous 28% ammonia (63 mL) was added and the mixture was heated at 100°C for 2 h. After cooling to room temperature, H 2 O was added (50 mL) and the solution was extracted with dichloromethane (3 × 75 mL). The combined organic layers were dried (Na 2 SO 4 ) and evaporated to afford (2R)-(+)-or (2S)-(−)-chromane-2-carboxamide as a white solid in 70% and 72% yield, respectively, which were used in the next step without further purification. (2R) To an ice-cooled solution of 1 M diborane in THF (45 mL, 45 mmol), a solution of (2R)-(+)-or (2S)-(−)-chromane-2-carboxamide (2.11 g, 11.9 mmol) in anhydrous THF (55 mL) was added dropwise under an argon atmosphere, and the mixture was stirred at room temperature overnight. Then, the reaction mixture was refluxed for 1 h and, after cooling to room temperature, 10% HCl (3.4 mL) was added. The solvent was evaporated, and the residue was basified to pH 8.5 with aqueous 10% NaOH and extracted with Et 2 O (6 × 50 mL). The combined organic layers were dried (Na 2 SO 4 ) and evaporated. To a solution of 4 equiv of the corresponding arylalkylamine (commercially available or 61−64) in dry acetonitrile (1 mL/mmol), a solution of 1 equiv of the appropriate bromo-or chloroalkyl derivative 42−60 in dry acetonitrile (4 mL/mmol) was added dropwise and under an argon atmosphere. The reaction mixture was stirred at 60°C overnight. Once at room temperature, the solvent was removed under reduced pressure and the residue was suspended in an aqueous solution of 20% K 2 CO 3 and extracted with dichloromethane (3 × 50 mL). The organic layer was dried (Na 2 SO 4 ), and the solvent was evaporated to dryness. The residue was purified by column chromatography using the appropriate eluent, to afford pure 4−35. The free amine was characterized (yield, R f , IR, NMR), dissolved in anhydrous Et 2 O (6 mL/mmol), and a commercial 1 M HCl(g)/Et 2 O solution (3 mL/mmol) was added. The hydrochloride salt was isolated by filtration or evaporation, washed with anhydrous Et 2 O, dried under high vacuum, and characterized (mp, elemental analysis). 2 (24) . Obtained from 49 and amine 64 in 40% yield. Chromatography: EtOAc. (25) . Obtained from 50 and amine 64 in 50% yield. Chromatography: EtOAc/EtOH, 9:1. (26) . Obtained from 51 and amine 64 in 35% yield. Chromatography: EtOAc/EtOH, 9:1. (27) . Obtained from 52 and amine 64 in 35% yield. Chromatography: EtOAc/EtOH, 95:5.
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2-{4-[(1-Naphthylmethyl)amino]butyl}tetrahydro-1H-pyrrolo-[1,2-c]imidazole-1,3(2H)-dione (4)
.
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Obtained from 53 and amine 64 in 36% yield. Chromatography: EtOAc/EtOH, 9:1; oil. R f (EtOAc/EtOH, 9:1) 0. 30 3-{8-[(3,4-Dihydro-2H-chromen-2-ylmethyl)amino]octyl}-1,3-thiazolidine-2,4-dione (35) . Obtained from 60 and amine 64 in 58% yield. Chromatography: EtOAc/EtOH, 9:1.
Binding Assays. For all receptors binding assays, male Sprague− Dawley rats (Rattus norvegicus albinus) weighing 180−200 g were killed by decapitation, and the brains were rapidly removed and dissected. Tissues were stored at −80°C for subsequent use and homogenized on a Polytron PT-10 homogenizer. Membrane suspensions were centrifuged on a Beckman J2-HS instrument.
5-HT 1A Receptor. Binding assays were performed by a modification of the procedure previously described by Clark et al. 60 The cerebral cortex was homogenized in 10 volumes of ice-cold Tris buffer (50 mM Tris-HCl, pH 7.7 at 25°C) and centrifuged at 28000g for 15 min. The membrane pellet was washed twice by resuspension and centrifugation. After the second wash the resuspended pellet was incubated at 37°C for 10 min. Membranes were then collected by centrifugation, and the final pellet was resuspended in 50 mM TrisHCl, 5 mM MgSO 4 , and 0.5 mM EDTA buffer (pH 7.4 at 37°C). Fractions of 100 μL of the final membrane suspension (about 5 mg/ mL of protein) were incubated at 37°C for 15 min with 0.6 nM [ 5-HT 2A Receptor. Binding assays were performed by a modification of the procedure previously described by Titeler et al. 61 The frontal cortex was homogenized in 60 volumes of ice-cold buffer (50 mM Tris-HCl, 0.5 mM Na 2 EDTA, 10 mM MgSO 4 , pH 7.4 at 25°C) and centrifuged at 30000g for 15 min at 4°C. The membrane pellet was washed by resuspension and centrifugation. After the second wash, the resuspended pellet was incubated at 37°C for 10 min. Membranes were then collected by centrifugation, and the final pellet was resuspended in 10 volumes of assay buffer (50 mM Tris-HCl, 0.5 mM Na 2 EDTA, 10 mM MgSO 4 , 0.1% ascorbic acid, 10 μM pargyline, pH 7.4 at 25°C). Fractions of 100 μL of the final membrane suspension (about 5 mg/mL of protein) were incubated at 37°C for 15 min with 0.4 nM [
3 H]ketanserin, in the presence or absence of the competing drug, in a final volume of 2 mL of assay buffer. Nonspecific binding was determined with 1 μM cinanserin and represented less than 15% of total binding. 5-HT 3 Receptor. Binding assays were performed by a modification of the procedure previously described by Wong et al. 62 The cerebral cortex was homogenized in 9 volumes of ice-cold 0.32 M sucrose and centrifuged at 1000g for 10 min at 4°C. The supernatant was centrifuged at 17000g for 20 min at 4°C. The membrane pellet was washed twice by resuspension in 60 volumes of ice-cold 50 mM TrisHCl buffer (pH 7.4 at 25°C) and centrifugation at 48000g for 10 min at 4°C. After the second wash, the resuspended pellet was incubated at 37°C for 10 min and centrifuged at 48000g for 10 min at 4°C. Membranes were resuspended in 2.75 volumes of assay buffer (50 mM Tris-HCl, 10 μM pargyline, 0.6 mM ascorbic acid, and 5 mM CaCl 2 , pH 7.4 at 25°C). Fractions of 100 μL of the final membrane suspension (about 2 mg/mL of protein) were incubated at 25°C for 30 min with 0.7 nM [ 3 H]LY 278584, in the presence or absence of the competing drug, in a final volume of 2 mL of assay buffer. Nonspecific binding was determined with 10 μM 5-HT and represented less than 20% of total binding.
5-HT 4
Receptor. Binding assays were performed by a modification of the procedure previously described by Grossman et al. 63 The striatum was homogenized in 15 volumes of ice-cold 50 mM HEPES buffer (pH 7.4 at 4°C) and centrifuged at 48000g for 10 min. The pellet was resuspended in 20 volumes of assay buffer (50 mM HEPES, pH 7.4 at 25°C). Fractions of 100 μL (about 5 mg/mL of protein) of the final membrane suspension were incubated at 37°C for 30 min with 0.1 nM [
3 H]GR 113808, in the presence or absence of the competing drug, in a final volume of 1 mL of assay buffer. Nonspecific binding was determined with 30 μM 5-HT and represented less than 20% of total binding. 5-HT 7 Receptor. Binding assays were performed by a modification of the procedure previously described by Aguirre et al. 64 The hypothalamus was homogenized in 5 mL of ice-cold Tris buffer (50 mM Tris-HCl, pH 7.4 at 25°C) and centrifuged at 48000g for 10 min. The membrane pellet was washed by resuspension and centrifugation, and then the resuspended pellet was incubated at 37°C for 10 min. Membranes were then collected by centrifugation, and the final pellet was resuspended in 100 volumes of ice-cold assay buffer (50 mM TrisHCl, 4 mM CaCl 2 , 1 mg/mL ascorbic acid, 0.01 mM pargyline, and 3 μM pindolol 65 buffer (pH 7.4 at 25°C)). Fractions of 400 μL of the final membrane suspension were incubated at 23°C for 120 min with 0.5 nM [
3 H]-5-CT, in the presence or absence of the competing drug, in a final volume of 0.5 mL of assay buffer. Nonspecific binding was determined with 10 μM 5-HT and represented less than 15% of total binding. D 2 Receptor. Binding assays were performed by a modification of the procedure previously described by Leysen et al. 66 The striatum was homogenized in 50 mM Tris-HCl (pH 7.4 at 25°C) and centrifuged at 48000g for 10 min. The pellet was resuspended and centrifuged twice as before. The final pellet was resuspended in 20 volumes of assay buffer (50 mM Tris-HCl (pH 7.1 at 25°C) containing 120 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , and 5.7 mM ascorbic acid). Fractions of the final membrane suspension (125−150 μg of protein) were incubated at 37°C for 15 min with 0.11 nM [
3 H]spiperone, in the presence or absence of six concentrations of the competing drug, in a final volume of 0.55 mL of the assay buffer (pH 7.4 at 25°C). Nonspecific binding was determined with 1 μM (+)-butaclamol and represented less than 20% of total binding. α 1 Adrenoceptor. Binding assays were performed by a modification of the procedure previously described by Ambrosio et al. 67 The cerebral cortex was homogenized in 20 volumes of ice-cold buffer (50 mM Tris-HCl, 10 mM MgCl 2 , pH 7.4 at 25°C) and centrifuged at 30000g for 15 min. The pellet was washed twice by resuspension and centrifugation. The final pellet was resuspended in 20 volumes of the assay buffer. Fractions of the final membrane suspension (about 250 μg of protein) were incubated at 25°C for 30 min with 0.2 nM [
3 H]prazosin, in the presence or absence of six concentrations of the competing drug, in a final volume of 2 mL of the assay buffer. Nonspecific binding was determined with 10 μM phentolamine and represented less than 20% of total binding.
8-OH-DPAT-Induced Hypothermia in Mice. The procedures used for these studies were based on previously described methods. 68 Briefly, male Swiss mice (23−28 g) were housed in groups of five, and body temperature was measured with a lubricated digital thermometer probe (pb0331, Panlab, Barcelona) inserted to a depth of 2 cm into the rectum of the mice. Temperature was recorded at 15, 30, and 60 min, after injection of 8-OH-DPAT or the compound to be tested. To study the antagonism to 8-OH-DPAT-induced hypothermia, compounds or vehicle (control) were administered intraperitoneally (ip) 30 min before the injection of 8-OH-DPAT (0.5 mg/kg, subcutaneously). The hypothermic response to 8-OH-DPAT was measured as the maximum decrease in body temperature recorded in this period. The results were expressed as change in body temperature with respect to basal temperature, measured at the beginning of the experiment. The obtained data were analyzed by Anova followed by Student−Newman−Keuls test.
cAMP Formation in HeLa Cells Transfected with the h5-HT 1A R. 69 A HeLa cell line permanently expressing the h5-HT 1A R gene (kindly donated by Cajal Institute, Madrid) was cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 2 mM glutamine, 1 mM pyruvate, and 10% heat-inactivated fetal calf serum (FCS). Subcultures were made by using 0.025% trypsin in phosphate buffered saline (PBS). Cultures were maintained at 37°C in an air/CO 2 (95:5) water-saturated atmosphere. cAMP experiments were carried out with cultures grown for 2−3 days in 8-well culture plates with 2 mL medium/well.
Cultures (about 7.5 × 10 4 cells/well) were washed with PBS and incubated for 10 min with 1 mL of PBS containing 0.5 mM isobutylmethylxanthine and 10 μM forskolin in the presence or absence of test compounds. The medium was then aspirated, and the reaction stopped by addition of 600 μL of ice-cold ethanol. Two hours later, ethanol was taken into an Eppendorf tube to be lyophilized, and the resulting pellet was resuspended in 100 μL of assay buffer (Kit Amersham SPA, RPA 538) and cAMP was quantified by RIA. To study the antagonism to 8-OH-DPAT-induced inhibition of forskolininduced cAMP formation, test compounds were preincubated 20 min before the addition of forskolin and 8-OH-DPAT.
Neurotoxicity Assays in Cell Cultures. Primary neuronal cultures were prepared from hippocampi of fetal Wistar rats at embryonic day 18 (E18). After dissection and mechanical dissociation, cells were cultured on poly-L-lysine coated plates at 37°C in a humidified 5% CO 2 atmosphere. Two types of cell cultures were prepared. For mixed neuronal and glial cells cultures, cells were maintained in Neurobasal medium (Invitrogen) containing 0.5 mM glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin and supplemented with 10% FCS. For the preparation of neuronal cellenriched cultures, FCS was substituted by 2% B27 supplement (Invitrogen).
Neurotoxicity studies were performed after 11 days in vitro. To determine the protection against apoptotic cell death induced by serum deprivation, culture medium was replaced by saline in mixed cultures, and cells were incubated in the presence of test compounds for 24 h. To study the protection against glutamate toxicity, 1 mM glutamate was added to neuron-enriched cultures for 22 h, and different concentrations of test compounds (1 nM to 10 μM) were added 30 min before glutamate. Exposure to oxygen and glucose deprivation in neuron-enriched cultures was performed as described. 70 Culture medium was replaced by a solution containing (mM): 130 NaCl, 5.4 KCl, 1.8 CaCl 2, 26 NaHCO 3, 0.8 MgSO 4, 1.18 NaH 2 PO 4 , and 25 2-desoxy-D-glucose. Cells were transferred to an anaerobic chamber (Forma Scientific, Hucoa-Erloss) containing 95% N 2 /5% CO 2 at 37°C for 150 min. After this time, the solution was replaced by DMEM medium supplemented with 33 mM glucose, and plates were incubated for 18 h in 5% CO 2 atmosphere. Test compounds were added at the time of initiating oxygen-glucose deprivation. Cell survival was estimated by measuring the activity of mitocondrial dehydrogenase on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), as described.
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Focal Cerebral Ischemia in Rats. Focal cerebral ischemia was produced in male Sprague−Dawley rats by permanent intraluminal MCAO, as previously reported. 72, 73 The day before ischemia, anesthesia was induced with 4% halothane. Rats were placed in the prone position on a stereotaxic frame, and anesthesia was maintained with 1.5−2% halothane. The left femoral artery was cannulated to monitor mean arterial blood pressure, and body temperature was maintained at 37.5°C with a heating blanket connected to a rectal probe. A 2.6 cm length of 3−0 monofilament nylon suture heatblunted at the tip was introduced into the external carotid artery through a puncture. The nylon suture was gently advanced into the internal carotid artery and circle of Willis until the origin of the MCA was reached, at approximately 22 mm from the carotid bifurcation. Infarct volume was measured 24 h later. Rats were killed while under halothane anesthesia, and the brains were rapidly frozen and kept at −20°C. Coronal brain sections of 20 μm were obtained with a cryostat and stained with a 1% solution of the mitochondrial dye TTC for 10 min. The infarcted area was identified macroscopically by pallor and microscopically by structural disorganization and histologic signs of neuronal and tissular damage. Infarct area was measured in each stained section with an image analyzing system (AIM Image Research). Test compounds were iv administered (intravenously bolus injection) one hour before ischemia and one hour later or, alternatively, were given by continuous iv infusion.
Molecular Modeling. Modeler v9.5 74 was used to build a homology model of the human 5-HT 1A R using the crystal structure of the β 2 -adrenergic receptor (PDB code 2RH1) 46 as template. The general Amber force field (GAFF) and HF/6-31G*-derived RESP atomic charges were used for the ligand. Molecular dynamics simulation of the ligand−receptor complex were performed with the Sander module of AMBER 10 75 using the protocol previously described. ■ ABBREVIATIONS USED DMEM, Dulbecco's modified Eagle medium; FCS, fetal calf serum; GPCR, G protein-coupled receptor; h5-HT 1A R, human 5-HT 1A receptor; ip, intraperitoneally; iv, intravenously; MCAO, occlusion of the middle cerebral artery; PBS, phosphate buffered saline; TM, transmembrane
